This article provides key insights and suggested best practices for managed care to improve patient care in MPS disorders, which may also be relevant to other rare and ultra-rare conditions.
Myths & Misconceptions That Impact Appropriate Treatment for Opioid Use Disorder (OUD)
Substance use disorder (SUD) is a pervasive, costly, and devastating health condition. Appropriate treatment can positively impact patient outcomes and health care costs; however, treatment decisions are often influenced by myths associated with treatment for SUD and opioid use disorder (OUD). The health care system, patients, payers, and providers benefit when patients are successful with OUD treatment. This article highlights five myths about treatment for OUD, provides context regarding current guidance, and offers suggestions for how managed care organizations (MCOs) can support care for patients with addiction through a chronic health model.
Related
As part of a multi-year RWE initiative, AMCP Research Institute partnered with IQVIA, payers, pharmaceutical companies, and others to design payer-focused RWE standards that were published in JMCP in September, 2025.
AMCP’s guidance translates CMS’s expectations for patient centered, evidence informed formulary decisions into practical steps payers can act on today without adding unnecessary burden to P&T workflows.
Featured News & Resources
See Full Calendar
Other Events
AMCP Ohio-Kentucky Day of Education 2026
Other Events
Mountain West Pharmacy Summit 2026
Other Events
Midwest 2026 Chicago Day of Education
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
